Showing 1 posts of 1 posts found.
NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …
Lonza and Engitix partner to develop next-generation antibody-drug conjugates
Simris Group appoints Tiffany J Vora as Strategic Advisor
Cizzle Biotechnology expands US rollout of lung cancer blood test
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide